Researchers are reevaluating approaches to treating metastatic prostate cancer, with studies examining various aspects such as targeted therapy, corticosteroid use, and biomarker strategies. The reexamination of treatment methods is not limited to prostate cancer, as similar reassessments are being made in other types of cancer, including gastric cancer and urothelial cancer. The scope of the reevaluation extends to broader considerations, including end-of-life care and the potential impact of cancer labeling on patient outcomes.